[Treatment of systemic hemolymphopathies and of epithelial and connective-tissue neoplasms with a methylhydrazine derivative].
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy*; D014067:Tonsillar Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D006834:Hydrazines
Trattamento delle emolinfopatie sistemiche e delle neoplasie epiteliali E CONNETTIVALI CON UN DERIVATO DELLA METILIDRAZINA.